Mesa Laboratories, Inc. (NASDAQ:MLAB – Get Free Report) CAO Lyndsey Elizabeth Crennen sold 442 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $39,559.00. Following the sale, the chief accounting officer owned 2,020 shares of the company’s stock, valued at $180,790. This trade represents a 17.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Lyndsey Elizabeth Crennen also recently made the following trade(s):
- On Tuesday, June 16th, Lyndsey Elizabeth Crennen sold 118 shares of Mesa Laboratories stock. The stock was sold at an average price of $101.27, for a total value of $11,949.86.
Mesa Laboratories Stock Performance
Shares of NASDAQ MLAB traded down $0.03 during trading hours on Tuesday, hitting $93.20. 104,033 shares of the company’s stock were exchanged, compared to its average volume of 138,588. The company’s 50-day moving average price is $101.95 and its 200-day moving average price is $90.98. Mesa Laboratories, Inc. has a 1-year low of $55.45 and a 1-year high of $113.99. The stock has a market capitalization of $514.93 million, a price-to-earnings ratio of 77.67 and a beta of 0.94. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.72 and a quick ratio of 1.29.
Mesa Laboratories Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Monday, June 15th. Shareholders of record on Friday, May 29th were issued a $0.16 dividend. The ex-dividend date of this dividend was Friday, May 29th. This represents a $0.64 dividend on an annualized basis and a yield of 0.7%. Mesa Laboratories’s dividend payout ratio is 53.33%.
Analyst Ratings Changes
Separately, Weiss Ratings lowered shares of Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, June 3rd. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $94.00.
Get Our Latest Research Report on Mesa Laboratories
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of MLAB. Simcoe Capital Management LLC acquired a new position in shares of Mesa Laboratories in the 3rd quarter valued at $12,794,000. Boston Partners raised its position in Mesa Laboratories by 2,009.5% in the third quarter. Boston Partners now owns 114,357 shares of the medical instruments supplier’s stock worth $7,664,000 after purchasing an additional 108,936 shares in the last quarter. Roubaix Capital LLC bought a new position in Mesa Laboratories during the third quarter worth about $5,137,000. Millennium Management LLC lifted its stake in Mesa Laboratories by 131.9% during the third quarter. Millennium Management LLC now owns 133,817 shares of the medical instruments supplier’s stock worth $8,967,000 after purchasing an additional 76,107 shares during the period. Finally, Mason Capital Management LLC acquired a new stake in Mesa Laboratories during the third quarter valued at approximately $4,711,000. 90.60% of the stock is owned by institutional investors.
About Mesa Laboratories
Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.
The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.
See Also
- Five stocks we like better than Mesa Laboratories
- Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning
- Apple’s Intel Deal Arrives at the Right Time for Its Stock
- Liquid Gold: The AI Cooling Retrofit Trade
- 3 Dividend Stocks Under $30 to Anchor Your Portfolio
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
